Article

Rheumatology Network's Top 5: July 9, 2022

Author(s):

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending July 9, 2022.

Early Methotrexate Can Alter Disease Course in Those At-Risk of Rheumatoid Arthritis

Use of methotrexate in the prearthritis stage of joint symptoms and subclinical inflammation could alter the disease course of clinical arthritis.

David Felson, MD, MPH: Assessing Disease Activity in Patients with RA and Low Joint Count

David Felson, MD, MPH, discusses his recent study, “Meaning of patient global assessment when joint counts are low in rheumatoid arthritis.”

Is There a Link Between Maternal Infection and Juvenile Idiopathic Arthritis?

Previous attempts to make associations between JIA and prenatal maternal infection is difficult due to the rarity of JIA diagnosis and recall bias.

Rheumatoid Arthritis Quiz: Activity Trackers and RA

Many people now use activity trackers to assess their activity levels, but what role can these devices play in managing rheumatoid arthritis patients? Test your knowledge with this quiz.

FDA Approves Pegloticase Injection Plus Methotrexate for Patients with Uncontrolled Gout

The decision was based on results from the MIRROR trial, which evaluated the concomitant use of pegloticase with methotrexate.

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.